Consistent with the GI50 data as shown in Fig. 2A, copanlisib inhibited phosphorylation and activation of AKT/mTOR pathway more robustly than idelalisib in all three MCC cell lines (Fig. 4B). This evidence concerns the gene AKT1 and Merkel cell skin cancer.